Under-Promising and Over-Delivering: Why Allergan Is a Buy

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn


Allergan Inc. (NYSE:AGN) has been one of the best pharmaceutical/biotech names for growth in the last two years rising some 98 percent in that time frame. The company is involved in selling several different healthcare products that it discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments: Specialty Pharmaceuticals and Medical Devices.

The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease. It also markets Botox for certain therapeutic and aesthetic indications as well as skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products.

The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders. The company sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. It focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, and general practitioners to makes sales. Given that it has high demand products and solid management, the company continues to absolutely deliver.

In its most recent quarter, Allergan saw $1.37 diluted earnings per share attributable to stockholders compared to $1.17 diluted earnings per share attributable to stockholders for the second-quarter of 2013. That is some serious growth for such a large company. These earnings also beat analyst consensus estimates. Allergan reported $1.51 non-GAAP diluted earnings per share attributable to stockholders compared to $1.22 non-GAAP diluted earnings per share attributable to stockholders for the second quarter of 2013, a 23.8 percent increase. These numbers came from tremendous revenues.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business